FrancophonIA/ELRC3.0 huggingface dataset:
English: Retacrit 1 000 IU/0.3 ml solution for injection in pre-filled syringe EU/1/07/431/001 1 pre-filled syringe EU/1/07/431/002 6 pre-filled syringes EU/1/07/431/026 1 pre-filled syringe with needle guard EU/1/07/431/027 6 pre-filled syringes with needle guard EU/1/07/431/054 1 pre-filled syringe with needle-trap EU/1/07/431/055 6 pre-filled syringes with needle-trap
Estonian: Retacrit 1000 RÜ/0,3 ml süstelahus süstlis EU/1/07/431/001 1 süstel EU/1/07/431/002 6 süstlit EU/1/07/431/026 1 nõelakaitsega süstel EU/1/07/431/027 6 nõelakaitsega süstlit EU/1/07/431/054 1 nõelalukuga süstel EU/1/07/431/055 6 nõelalukuga süstlit
English: Retacrit 8 000 IU/0.8 ml solution for injection in pre-filled syringe 1 pre-filled syringe with 0.8 ml solution for injection contains 8 000 international units (IU) epoetin zeta* (recombinant human erythropoietin).
Estonian: 1 süstel 0,8 ml süstelahusega sisaldab 8000 rahvusvahelist ühikut (RÜ) dzeetaepoetiini* (rekombinantne inimese erütropoetiin).
English: Retacrit 40 000 IU/1 ml solution for injection in pre-filled syringe EU/1/07/431/019 1 pre-filled syringe EU/1/07/431/024 4 pre-filled syringes EU/1/07/431/025 6 pre-filled syringes EU/1/07/431/044 1 pre-filled syringe with needle guard EU/1/07/431/049 4 pre-filled syringes with needle guard EU/1/07/431/050 6 pre-filled syringes with needle guard EU/1/07/431/053 4 (4 x 1) pre-filled syringes (multipack) EU/1/07/431/076 1 pre-filled syringe with needle-trap
Estonian: Retacrit 40 000 RÜ/1 ml süstelahus süstlis EU/1/07/431/019 1 süstel EU/1/07/431/024 4 süstlit EU/1/07/431/025 6 süstlit EU/1/07/431/044 1 nõelakaitsega süstel EU/1/07/431/049 4 nõelakaitsega süstlit EU/1/07/431/050 6 nõelakaitsega süstlit EU/1/07/431/053 4 süstlit (4 x 1 mitmikpakend) EU/1/07/431/076 1 nõelalukuga süstel EU/1/07/431/077 4 nõelalukuga süstlit EU/1/07/431/078 6 nõelalukuga süstlit
English: Retacrit 20 000 IU/0.5 ml solution for injection in pre-filled syringe
Estonian: Retacrit 20 000 RÜ/0,5 ml süstelahus süstlis
English: Retacrit 4 000 IU/0.4 ml solution for injection in pre-filled syringe
Estonian: Retacrit 4000 RÜ/0,4 ml süstelahus süstlis
English: 1 pre-filled syringe without needle guard containing 0.6 ml solution for injection 6 pre-filled syringes without needle guard containing 0.6 ml solution for injection 1 pre-filled syringe with needle guard containing 0.6 ml solution for injection 6 pre-filled syringes with needle guard containing 0.6 ml solution for injection 1 pre-filled syringe with needle-trap containing 0.6 ml solution for injection 6 pre-filled syringes with needle-trap containing 0.6 ml solution for injection
Estonian: 1 nõelakaitseta süstel 0,6 ml süstelahusega 6 nõelakaitseta süstlit 0,6 ml süstelahusega 1 nõelakaitsega süstel 0,6 ml süstelahusega 6 nõelakaitsega süstlit 0,6 ml süstelahusega 1 nõelalukuga süstel 0,6 ml süstelahusega 6 nõelalukuga süstlit 0,6 ml süstelahusega
English: Excipients with known effect Each pre-filled syringe contains 0.30 mg phenylalanine.
Estonian: Teadaolevat toimet omavad abiained Iga süstel sisaldab 0,30 mg fenüülalaniini.
English: Adult surgery patients in an autologous predonation programme
Estonian: Autoloogse eeldoonorluse programmi täiskasvanud kirurgiapatsiendid
English: 1 pre-filled syringe with 0.4 ml solution for injection contains 4 000 international units (IU) epoetin zeta (recombinant human erythropoietin).
Estonian: 1 süstel, milles on 0,4 ml süstelahust, sisaldab 4000 rahvusvahelist ühikut (RÜ) dzeetaepoetiini (rekombinantne inimerütropoetiin).
English: Retacrit 40 000 IU injection epoetin zeta
Estonian: Retacrit 40 000 RÜ süstelahus dzeetaepoetiin i.v./s.c.
English: Retacrit 40 000 IU/1 ml solution for injection in pre-filled syringe
Estonian: Retacrit 40 000 RÜ/1 ml süstelahus süstlis
English: Appropriate adjustment of the dose should be made in order to maintain haemoglobin values within the desired concentration range between 10 g/dL to 12 g/dL (6.2 to 7.5 mmol/L).
Estonian: Annust tuleb vastavalt kohandada nii, et hemoglobiini väärtus püsiks soovitud kontsentratsioonivahemikus 10 g/dl kuni 12 g/dl (6,2...7,5 mmol/l).
English: 1 pre-filled syringe contains 1 000 IU epoetin zeta.
Estonian: 1 süstel sisaldab 1000 RÜ dzeetaepoetiini.
English: 1 pre-filled syringe with 0.6 ml solution for injection contains 2 000 international units (IU) epoetin zeta (recombinant human erythropoietin).
Estonian: 1 süstel, milles on 0,6 ml süstelahust, sisaldab 2000 rahvusvahelist ühikut (RÜ) dzeetaepoetiini (rekombinantne inimerütropoetiin).
English: • increased risk of death when administered to achieve a haemoglobin concentration level of 12 g/dL (7.5 mmol/L) in patients with active malignant disease receiving neither chemotherapy nor radiation therapy.
Estonian: suurem surma risk aktiivse maliigse haigusega patsientidel, kes ei saa ei keemiaravi ega kiiritusravi, kui ravimit manustati eesmärgiga suurendada hemoglobiini kontsentratsioon väärtuseni 12 g/dl (7,5 mmol/l).
English: Retacrit 6 000 IU/0.6 ml solution for injection in pre-filled syringe
Estonian: Retacrit 6000 RÜ/0,6 ml süstelahus süstlis
English: Retacrit 4 000 IU injection epoetin zeta
Estonian: Retacrit 4000 RÜ süstelahus dzeetaepoetiin i.v./s.c.
English: Retacrit 2 000 IU/0.6 ml solution for injection in pre-filled syringe EU/1/07/431/003 1 pre-filled syringe EU/1/07/431/004 6 pre-filled syringes EU/1/07/431/028 1 pre-filled syringe with needle guard EU/1/07/431/029 6 pre-filled syringes with needle guard EU/1/07/431/056 1 pre-filled syringe with needle-trap EU/1/07/431/057 6 pre-filled syringes with needle-trap
Estonian: Retacrit 2000 RÜ/0,6 ml süstelahus süstlis EU/1/07/431/003 1 süstel EU/1/07/431/004 6 süstlit EU/1/07/431/028 1 nõelakaitsega süstel EU/1/07/431/029 6 nõelakaitsega süstlit EU/1/07/431/056 1 nõelalukuga süstel EU/1/07/431/057 6 nõelalukuga süstlit
English: Retacrit 6 000 IU injection epoetin zeta
Estonian: Retacrit 6000 RÜ süstelahus dzeetaepoetiin i.v./s.c.
English: Excipients with known effect Each pre-filled syringe contains 0.50 mg phenylalanine.
Estonian: Teadaolevat toimet omavad abiained Iga süstel sisaldab 0,50 mg fenüülalaniini.
English: EU/1/07/431/077 4 pre-filled syringes with needle-trap EU/1/07/431/078 6 pre-filled syringes with needle-trap
Estonian: EU/1/07/431/039 6 nõelakaitsega süstlit EU/1/07/431/066 1 nõelalukuga süstel EU/1/07/431/067 6 nõelalukuga süstlit
English: Retacrit 3 000 IU injection epoetin zeta
Estonian: Retacrit 3000 RÜ süstelahus dzeetaepoetiin i.v./s.c.
English: Retacrit 10 000 IU/1 ml solution for injection in pre-filled syringe
Estonian: Retacrit 10 000 RÜ/1 ml süstelahus süstlis
English: Retacrit 5 000 IU/0.5 ml solution for injection in pre-filled syringe 1 pre-filled syringe with 0.5 ml solution for injection contains 5 000 international units (IU) epoetin zeta* (recombinant human erythropoietin).
Estonian: 1 süstel 0,5 ml süstelahusega sisaldab 5000 rahvusvahelist ühikut (RÜ) dzeetaepoetiini* (rekombinantne inimese erütropoetiin).
English: Treatment of symptomatic anaemia in adult and paediatric chronic renal failure patients
Estonian: Sümptomaatilise aneemia ravi kroonilise neerupuudulikkusega täiskasvanutel ja lastel
English: Retacrit 2 000 IU injection epoetin zeta
Estonian: Retacrit 2000 RÜ süstelahus dzeetaepoetiin i.v./s.c.
English: Retacrit 2 000 IU
Estonian: Retacrit 2000 RÜ
English: Retacrit 1 000 IU/0.3 ml solution for injection in pre-filled syringe
Estonian: Retacrit 1000 RÜ/0,3 ml süstelahus süstlis
English: Appropriate adjustment of dose and dose intervals should be made in order to maintain haemoglobin values at the desired level: haemoglobin between 10 g/dL to 12 g/dL (6.2 to 7.5 mmol/L).
Estonian: Annust ja annustamisintervalle tuleb vastavalt kohandada, et hemoglobiini väärtus püsiks soovitud kontsentratsioonivahemikus 10 g/dl kuni 12 g/dl (6,2...7,5 mmol/l).
English: Retacrit 30 000 IU/0.75 ml solution for injection in pre-filled syringe 1 pre-filled syringe with 0.75 ml solution for injection contains 30 000 international units (IU) epoetin zeta* (recombinant human erythropoietin).
Estonian: 1 süstel 0,75 ml süstelahusega sisaldab 30 000 rahvusvahelist ühikut (RÜ) dzeetaepoetiini* (rekombinantne inimese erütropoetiin).
English: Surgery patients in autologous predonation programmes
Estonian: Autoloogse eeldoonorluse programmis osalevad kirurgiapatsiendid
English: Do not remove the syringe's needle cover while allowing it to reach room temperature.
Estonian: Sel ajal, kui ravim soojeneb toatemperatuurini, ärge eemaldage süstlalt nõelakatet.
English: Retacrit 8 000 IU/0.8 ml solution for injection in pre-filled syringe EU/1/07/431/013 1 pre-filled syringe EU/1/07/431/014 6 pre-filled syringes EU/1/07/431/038 1 pre-filled syringe with needle guard EU/1/07/431/039 6 pre-filled syringes with needle guard EU/1/07/431/066 1 pre-filled syringe with needle-trap EU/1/07/431/067 6 pre-filled syringes with needle-trap
Estonian: Retacrit 8000 RÜ/0,8 ml süstelahus süstlis EU/1/07/431/013 1 süstel EU/1/07/431/014 6 süstlit EU/1/07/431/038 1 nõelakaitsega süstel
English: Retacrit 10 000 IU/1 ml solution for injection in pre-filled syringe 1 pre-filled syringe with 1.0 ml solution for injection contains 10 000 international units (IU) epoetin zeta* (recombinant human erythropoietin).
Estonian: 1 süstel 1,0 ml süstelahusega sisaldab 10 000 rahvusvahelist ühikut (RÜ) dzeetaepoetiini* (rekombinantne inimese erütropoetiin).
English: Retacrit 6 000 IU/0.6 ml solution for injection in pre-filled syringe 1 pre-filled syringe with 0.6 ml solution for injection contains 6 000 international units (IU) epoetin zeta* (recombinant human erythropoietin).
Estonian: 1 süstel 0,6 ml süstelahusega sisaldab 6000 rahvusvahelist ühikut (RÜ) dzeetaepoetiini* (rekombinantne inimese erütropoetiin).
English: Retacrit 20 000 IU/0.5 ml solution for injection in pre-filled syringe 1 pre-filled syringe with 0.5 ml solution for injection contains 20 000 international units (IU) epoetin zeta* (recombinant human erythropoietin).
Estonian: 1 süstel 0,5 ml süstelahusega sisaldab 20 000 rahvusvahelist ühikut (RÜ) dzeetaepoetiini* (rekombinantne inimese erütropoetiin).
English: Retacrit 1 000 IU injection epoetin zeta
Estonian: Retacrit 1000 RÜ süstelahus dzeetaepoetiin i.v./s.c.
English: Retacrit 4 000 IU/0.4 ml solution for injection in pre-filled syringe 1 pre-filled syringe with 0.4 ml solution for injection contains 4 000 international units (IU) epoetin zeta* (recombinant human erythropoietin).
Estonian: 1 süstel 0,4 ml süstelahusega sisaldab 4000 rahvusvahelist ühikut (RÜ) dzeetaepoetiini* (rekombinantne inimese erütropoetiin).
English: Convulsion
Estonian: Imendumine
English: 28 patches (7x 2mg/24h, 7x 4mg/24h, 7x 6mg/24h, 7x 8mg/24h)
Estonian: Transdermaalne plaaster transdermaalset plaastrit (7x 2mg/24h, 7x 4mg/24h, 7x 6mg/24h, 7x 8mg/24h)
English: Transdermal patch Transdermal use sachet (paper/LDPE/alu/ET copolymer PE/Alu/ ET copolymer/paper)
Estonian: Tugevus Ravimvorm Manustamistee Sisepakendi iseloomustus
English: 24 October 2011
Estonian: 24. oktoober 2011
English: The European Commission issued a decision on 24 October 2011.
Estonian: Euroopa Komisjon tegi otsuse 24. oktoobril 2011.
English: Outcome of a procedure under Article 29 of Directive 2001/83/EC as amended
Estonian: Muudetud direktiivi 2001/83/EÜ artikli 29 kohase menetluse tulemus
English: It is available as an oral solution (0.4 mg/ml).
Estonian: Seda turustatakse suukaudse lahusena (0,4 mg/ml).
English: EMA/863769/2011 Rev.1 EMEA/H/A-29/1308
Estonian: EMA/CHMP/582483/2011 Rev.1 EMEA/H/A-29/1308
English: This is a procedure where one Member State (the ‘reference Member State', in this instance Malta) assesses a medicine with a view to granting a marketing authorisation that will be valid in this country as well as in other Member States (the ‘concerned Member States', in this instance Belgium, Bulgaria, Cyprus, Germany, Greece, Portugal, Romania and the United Kingdom).
Estonian: See on menetlus, mille käigus üks liikmesriik (viiteliikmesriik, käesoleval juhul Malta) hindab ravimit, et otsustada, kas anda ravimile müügiluba, mis kehtib selles riigis ja ka teistes liikmesriikides (asjaomased liikmesriigid, käesoleval juhul Belgia, Bulgaaria, Kreeka, Küpros, Portugal, Rumeenia, Saksamaa ja Ühendkuningriik).
English: It works by entering cells and blocking the production of vascular endothelial growth factor (VEGF) and prostaglandins, substances that are involved in inflammation and swelling.
Estonian: See toimib sisenedes rakkudesse ja blokeerides endoteeli kasvuteguri (VEGF) ja prostaglandiinide (põletikus ja turses osalevad ained) tekke.
English: Dexamethasone Alapis is intended for use principally as an anti-inflammatory or immunosuppressant (a medicine that reduces the activity of the immune system) in a range of specific disorders affecting different parts of the body, including the blood, liver, kidney, stomach and gut, muscles, eye, lungs and skin, as well as in certain cancers and in the management of anaphylaxis (severe allergic reaction).
Estonian: Dexamethasone Alapist kavatsetakse kasutada peamiselt põletikuvastase või immuunsupressiivse (vähendab immuunsüsteemi aktiivsust) ravimina mitmete spetsiifiliste häirete korral eri kehaosades (sealhulgas veri, maks, neerud, magu ja soolestik, lihased, silmad, kopsud ja nahk) ning samuti teatud tüüpi vähktõve korral ja anafülaksia (raske allergiline reaktsioon) raviks.
English: What is Dexamethasone Alapis?
Estonian: Mis on Dexamethasone Alapis?
English: EMA/863769/2011
Estonian: EMA/CHMP/582483/2011
English: However, the Member States were not able to reach an agreement and the Maltese medicines regulatory agency referred the matter to the CHMP for arbitration on 30 May 2011.
Estonian: Liikmesriigid ei jõudnud kokkuleppele ja Malta ravimiamet tegi 30. mail 2011 inimravimite komiteele esildise vahekohtumenetluse alustamiseks.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefits of Dexamethasone Alapis outweigh its risks, and the marketing authorisation can be granted in Malta and in the following Member States of the EU: Belgium, Bulgaria, Cyprus, Germany, Greece, Portugal, Romania and the United Kingdom.
Estonian: Ravimiameti inimravimite komitee otsustas, et ravimi Dexamethasone Alapis kasulikkus on suurem kui sellega kaasnevad riskid ning ravimi müügiloa võib anda Maltal ja järgmistes ELi liikmesriikides: Belgia, Bulgaaria, Kreeka, Küpros, Portugal, Rumeenia, Saksamaa ja Ühendkuningriik.
English: The German medicines regulatory authority was of the opinion that the data submitted to support the application did not provide sufficient evidence to demonstrate the safety and effectiveness of Dexamethasone Alapis.
Estonian: Saksamaa ravimiamet oli arvamusel, et taotluse toetuseks esitatud andmed ei sisaldanud piisavalt tõendeid Dexamethasone Alapise ohutuse ja efektiivsuse kohta.
English: Based on evaluation of the currently available data and the scientific discussion within the Committee, the CHMP concluded that the data submitted was sufficient to show that Dexamethasone Alapis could be used safely and effectively based on the well established use of dexamethasone.
Estonian: Tuginedes praegu kättesaadavate andmete hindamisele ja komiteesisesele teaduslikule arutelule, jõudis inimravimite komitee järeldusele, et esitatud andmed olid piisavad, näitamaks, et Dexamethasone Alapist saab kasutada ohutult ja efektiivselt, tuginedes deksametasooni hästi tõestatud kasutusele.
English: The European Medicines Agency has completed an arbitration procedure following a disagreement among Member States of the European Union (EU) regarding the authorisation of the medicine Dexamethasone Alapis.
Estonian: Euroopa Ravimiamet on lõpetanud vahekohtumenetluse, mis algatati pärast seda, kui Euroopa Liidu liikmesriigid ei jõudnud kokkuleppele ravimi Dexamethasone Alapis heakskiitmises.
English: Alapis S.A. submitted Dexamethasone Alapis to Malta for a decentralised procedure.
Estonian: Alapis S.A. esitas Maltale ravimi Dexamethasone Alapis detsentraliseeritud menetluse taotluse.
English: The CHMP concluded that the benefits of Dexamethasone Alapis outweigh its risks, and therefore the marketing authorisation for Dexamethasone Alapis should be granted in all concerned Member States.
Estonian: Inimravimite komitee otsustas, et ravimi Dexamethasone Alapis kasulikkus on suurem kui sellega kaasnevad riskid ja soovitas anda ravimi müügiloa kõikides asjaomastes liikmesriikides.
English: Dexamethasone Alapis is a medicine that contains the active substance dexamethasone.
Estonian: Dexamethasone Alapis on ravim, mis sisaldab toimeainena deksametasooni.
English: Why was Dexamethasone Alapis reviewed?
Estonian: Miks ravimi Dexamethasone Alapis taotlus uuesti üle vaadati?
English: The active substance in Dexamethasone Alapis, dexamethasone, belongs to a group of anti-inflammatory medicines known as corticosteroids.
Estonian: Dexamethasone Alapise toimeaine deksametasoon kuulub põletikuvastaste ravimite kortikosteroidide klassi.
English: The grounds for the referral were that the application, which was supported by published literature rather than studies carried out with Dexamethasone Alapis, because dexamethasone has a history of well-established use in the EU for at least 10 years, was mainly supported by literature demonstrating the safety and efficacy of dexamethasone in tablet form rather than oral solution form and the bridging data provided were not considered adequate to conclude on the benefit-risk profile of the oral solution form.
Estonian: deksametasooni on hästi tõestatud kasutusele tuginedes kasutatud Euroopa Liidus vähemalt 10 aastat, toetas peamiselt kirjandus, mis tõendas deksametasooni ohutust ja efektiivsust manustatuna tableti, mitte suukaudse lahusena, ja esitatud vaheandmeid ei peetud piisavaks, et teha otsus ravimi suukaudse vormi kasulikkuse ja riskide suhte kohta.
English: The full EPAR and risk management plan summary for Pemetrexed Sandoz can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Pemetrexed Sandoze kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: A risk management plan has been developed to ensure that Pemetrexed Sandoz is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Pemetrexed Sandoze võimalikult ohutu kasutamine.
English: What measures are being taken to ensure the safe and effective use of Pemetrexed Sandoz?
Estonian: Mis meetmed võetakse, et tagada Pemetrexed Sandoze ohutu ja efektiivne kasutamine?
English: The full EPAR for the reference medicine can also be found on the Agency's website.
Estonian: Euroopa avaliku hindamisaruande täistekst võrdlusravimi kohta on samuti ravimiameti veebilehel.
English: The Committee recommended that Pemetrexed Sandoz be approved for use in the EU.
Estonian: Komitee soovitas Pemetrexed Sandoze kasutamise Euroopa Liidus heaks kiita.
English: • malignant pleural mesothelioma (a cancer of the lining of the lungs that is usually caused by exposure to asbestos), where it is used together with cisplatin in patients who have not received chemotherapy before and whose cancer cannot be removed by surgery;
Estonian: • pleura maliigne mesotelioom (kopsukelme vähk, mida tavaliselt põhjustab kokkupuude asbestiga), kusjuures Pemetrexed Sandozt kasutatakse koos tsisplatiiniga patsientidel, kes ei ole varem keemiaravi saanud ja kelle vähkkasvajat ei saa eemaldada kirurgiliselt;
English: To reduce side effects, patients should take a corticosteroid (a type of medicine that reduces inflammation) and folic acid (a type of vitamin), and receive injections of vitamin B12 during treatment with Pemetrexed Sandoz.
Estonian: Kõrvalnähtude vähendamiseks tuleb patsiendil võtta kortikosteroide (põletikuvastane ravim) ja foolhapet (teatud vitamiin) ning talle tuleb Pemetrexed Sandoze ravi ajal süstida B12-vitamiini.
English: No additional studies were needed as Pemetrexed Sandoz is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Alimta.
Estonian: Lisauuringuid ei olnud vaja, sest Pemetrexed Sandoz on infusioonina manustatav geneeriline ravim, mis sisaldab sama toimeainet kui võrdlusravim Alimta.
English: Because Pemetrexed Sandoz is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Pemetrexed Sandoz on geneeriline ravim, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Pemetrexed Sandoz has been shown to be comparable to Alimta.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Pemetrexed Sandoz sarnane toime ravimiga Alimta.
English: When Pemetrexed Sandoz is given with cisplatin, an ‘anti-emetic' medicine (to prevent vomiting) and fluids (to prevent dehydration) should also be given before or after the cisplatin dose.
Estonian: Kui Pemetrexed Sandozt antakse koos tsisplatiiniga, tuleb enne või pärast tsisplatiiniannuse manustamist anda antiemeetikumi (oksendamise ennetamiseks) ja vedelikke (dehüdratsiooni ennetamiseks).
English: • advanced non-small-cell lung cancer of the kind known as ‘non-squamous', where it is used either in combination with cisplatin in previously untreated patients or on its own in patients who have previously received cancer treatment.
Estonian: • kaugelearenenud mitteväikerakk-kopsuvähi muu kui lamerakuline vorm, kusjuures Pemetrexed Sandozt kasutatakse koos tsisplatiiniga patsientidel, keda ei ole varem ravitud, ja ainsa ravimina patsientidel, kes on varem vähiravi saanud.
English: This is a summary of the European public assessment report (EPAR) for Pemetrexed Sandoz.
Estonian: See on ravimi Pemetrexed Sandoz Euroopa avaliku hindamisaruande kokkuvõte.
English: For practical information about using Pemetrexed Sandoz, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Pemetrexed Sandoze kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: This means that Pemetrexed Sandoz is similar to a ‘reference medicine' already authorised in the European Union (EU) called Alimta.
Estonian: See tähendab, et Pemetrexed Sandoz on sarnane võrdlusravimiga Alimta, millel juba on Euroopa Liidus müügiluba.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Pemetrexed Sandoz, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Pemetrexed Sandoze omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: Pemetrexed Sandoz is a cancer medicine used to treat two types of lung cancer:
Estonian: Pemetrexed Sandoz on vähiravim, mida kasutatakse kaht tüüpi kopsuvähi raviks:
English: Other information about Pemetrexed Sandoz
Estonian: Muu teave Pemetrexed Sandoze kohta
English: For more information about treatment with Pemetrexed Sandoz, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Pemetrexed Sandozega toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: What is Pemetrexed Sandoz and what is it used for?
Estonian: Mis on Pemetrexed Sandoz ja milleks seda kasutatakse?
English: Pemetrexed Sandoz pemetrexed
Estonian: Pemetrexed Sandoz pemetrekseed
English: It is not intended to provide practical advice on how to use Pemetrexed Sandoz.
Estonian: Hindamisaruandes ei anta Pemetrexed Sandoze kasutamise praktilisi nõuandeid.